EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

about

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

Item

http://www.wikidata.org/entity/Q53698558

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

@en

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

@nl

type

Item

label

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

@en

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

@nl

prefLabel

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

@en

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

@nl

P1476

EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

@en

P2093

Dian-Sheng Zhong

http://www.w3.org/2001/XMLSchema#string

Hui Lv

http://www.w3.org/2001/XMLSchema#string

Qing-Hua Zhou

http://www.w3.org/2001/XMLSchema#string

Yi Shao

http://www.w3.org/2001/XMLSchema#string

P2860

Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties

Mammary stem cells, self-renewal pathways, and carcinogenesis

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma

Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Global cancer statistics, 2012

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

6655-6665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.8129

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29616128

http://www.w3.org/2001/XMLSchema#string

P932

5876419

http://www.w3.org/2001/XMLSchema#string